Dostarlimab
2022-1047
Phase 2 small_molecule active
Quick answer
Dostarlimab for Ovarian Clear Cell Carcinoma is a Phase 2 program (small_molecule) at LIXTE BIOTECHNOLOGY HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Indication
- Ovarian Clear Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active